about
Enhancement of intrarenal plasma membrane calcium pump isoform 1 expression in chronic angiotensin II-infused miceRenal tubule angiotensin II type 1 receptor-associated protein promotes natriuresis and inhibits salt-sensitive blood pressure elevationAngiotensin II Type 1 Receptor Binding Molecule ATRAP as a Possible Modulator of Renal Sodium Handling and Blood Pressure in Pathophysiology.Ambulatory blood pressure and tubulointerstitial injury in patients with IgA nephropathyEffects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemiaPotential beneficial impact of angiotensin receptor blockers on arterial stiffness in hypertension.ATRAP Expression in Brown Adipose Tissue Does Not Influence the Development of Diet-Induced Metabolic Disorders in Mice.Factors associated with a vicious cycle involving a low nephron number, hypertension and chronic kidney disease.Circadian blood pressure abnormalities in patients with primary nephrotic syndrome.Renal histopathological findings in relation to ambulatory blood pressure in chronic kidney disease patients.Adipocyte-Specific Enhancement of Angiotensin II Type 1 Receptor-Associated Protein Ameliorates Diet-Induced Visceral Obesity and Insulin Resistance.Angiotensin II Type 1 Receptor-Associated Protein Regulates Kidney Aging and Lifespan Independent of Angiotensin.Glomerulopathy Associated With Moderate Obesity.Glomerular Density and Volume in Renal Biopsy Specimens of Children with Proteinuria Relative to Preterm Birth and Gestational Age.Possible impact of electronegative LDL on atherosclerosis in type 2 diabetes.Within-visit blood pressure variability and cardiovascular risk factors in hypertensive patients with non-dialysis chronic kidney disease.Angiotensin receptor-binding molecule in leukocytes in association with the systemic and leukocyte inflammatory profile.Angiotensin II Type 1 Receptor-associated Protein Inhibits Angiotensin II-induced Insulin Resistance with Suppression of Oxidative Stress in Skeletal Muscle Tissue.Effect of single-pill irbesartan/amlodipine combination-based therapy on clinic and home blood pressure profiles in hypertension with chronic kidney diseases.An angiotensin II type 1 receptor binding molecule has a critical role in hypertension in a chronic kidney disease model.Reduction of proteinuria by therapeutic intervention improves the renal outcome of elderly patients with IgA nephropathy.Possible therapeutic impact of the iron chelation on renal fibrosis.Possible interesting link between Janus kinase 2 mutation and renovascular hypertension.Bowman Capsule Volume and Related Factors in Adults With Normal Renal Function.Volume Ratio of Glomerular Tufts to Bowman Capsules and Renal Outcomes in NephrosclerosisEffects of rikkunshito on renal fibrosis and inflammation in angiotensin II-infused miceGlomerular Density in Biopsy-Proven Hypertensive NephrosclerosisIs granular formulation of lanthanum carbonate more effective than chewable tablets?Heterogeneous distribution of glomerular size in adult kidneys with normal renal functionComparison of direct renin inhibitor and angiotensin II receptor blocker on clinic and ambulatory blood pressure profiles in hypertension with chronic kidney diseaseEffects of Rikkunshito treatment on renal fibrosis/inflammation and body weight reduction in a unilateral ureteral obstruction model in miceEstimation of nephron number in living humans by combining unenhanced computed tomography with biopsy-based stereologyBiopsy-based estimation of total nephron number in Japanese living kidney donorsAngiotensin II type 1 receptor-associated protein deficiency attenuates sirtuin1 expression in an immortalised human renal proximal tubule cell lineTime-averaged proteinuria during follow-up and renal prognosis in patients with biopsy-proven benign nephrosclerosis[A case of glomerulopathy associated with the vascular endothelial growth factor inhibitor bevacizumab]
P50
Q33800266-87CC35FB-6102-49C7-A6C2-40317779A219Q35354119-27AEC9B2-2AF3-419A-8572-90336AF341B7Q35752131-2CE57F62-2EA7-48F9-A627-0DEBC77D70D0Q36306742-4E17B104-D83F-4203-B315-DD8A1AA25745Q36357758-F67A2B58-DC80-462D-84D7-1A9BAE62D2E3Q37121439-14DD6FFB-0B86-4F0A-991B-F283007FE4CCQ37729369-A56B5103-A1BA-4854-9489-2729917AC411Q38530387-4944472C-9BA0-45A9-8C2E-4E2753D50F94Q38911340-934DCF2A-C11B-498A-8DA5-A3D7E91101D9Q39127448-0852DE3A-D704-482C-8049-B90DC8C484F8Q41103828-4B4895AC-5F2A-48CC-994D-88BF86ADCACBQ41628398-E84B5E5D-5AB5-4136-9C19-DE128108C7BDQ47106733-B9ECA875-95B9-43E3-A7DD-2470AC55B6FEQ47817930-47B0C843-98BB-4E67-9215-EE52591246A2Q47887907-AAFE22AE-062E-4F0B-B57B-FC6A00095CF9Q48246287-5556C831-4679-4716-95F7-EFE233F78726Q48499987-6AA967A1-E95E-41A0-981D-EE1B2B4FB854Q49345079-344BDCBE-5A85-424C-AA43-0D618A281783Q51019364-66E03760-47E4-4839-B5B0-8044DA61A45DQ51194907-10C7CE76-AC33-4508-BA8A-E382C77B57F8Q53188667-6490949A-0BE8-463B-9C26-7F864CD4BB95Q53543849-1E66337E-CD55-476D-A6A7-34C54337773FQ54116026-23838BB9-7351-4FF0-BA25-0C06E96DC183Q55212252-C9CBCF3C-32C5-4272-89E9-1A3FBC4296B9Q57789490-FDDF8B30-C3AF-4EBF-A8E5-D8FECD6491C5Q64106682-A940C77D-86AE-4444-9CB7-EB13D5C4EA85Q86619317-FA390A68-FC99-4F89-A72A-CA9CC311F319Q88129691-6957A261-34A8-48CD-8C4C-CC1B190A83F3Q88635547-9B4A95A8-ACC3-4F4B-BDDC-282E5B863BE3Q88939502-09E79F3A-F1C2-43D4-92C2-3E6782CAF28EQ89555840-757002E2-7C8A-4B0E-A184-0B8E203D92F0Q90575028-28BC36C1-02C9-43EB-8336-A80EE6C8D2A2Q91011793-1EE032F6-7FAE-465A-97C2-18C37BED2A1AQ91260276-65DE966F-D9C5-4D65-9F97-17BAD3ED5947Q91797201-6E889299-927B-4BF3-8137-F1EAA2E893EBQ95486268-A458CCE3-B339-4B8F-A3BF-569DE35FEE08
P50
description
researcher ORCID ID = 0000-0003-1918-0390
@en
name
Kotaro Haruhara
@ast
Kotaro Haruhara
@en
Kotaro Haruhara
@es
Kotaro Haruhara
@nl
type
label
Kotaro Haruhara
@ast
Kotaro Haruhara
@en
Kotaro Haruhara
@es
Kotaro Haruhara
@nl
prefLabel
Kotaro Haruhara
@ast
Kotaro Haruhara
@en
Kotaro Haruhara
@es
Kotaro Haruhara
@nl
P1153
56224285800
P31
P496
0000-0003-1918-0390